EP3518904A1 - Composition pharmaceutique comprenant du deferasirox - Google Patents

Composition pharmaceutique comprenant du deferasirox

Info

Publication number
EP3518904A1
EP3518904A1 EP17769011.2A EP17769011A EP3518904A1 EP 3518904 A1 EP3518904 A1 EP 3518904A1 EP 17769011 A EP17769011 A EP 17769011A EP 3518904 A1 EP3518904 A1 EP 3518904A1
Authority
EP
European Patent Office
Prior art keywords
tablet
deferasirox
present
amount
film
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP17769011.2A
Other languages
German (de)
English (en)
Inventor
Sara FRADERA GELABERT
Marta VIVANCOS MARTINEZ
Lisardo ÁLVAREZ FERNÁNDEZ
Jose VELADA CALZADA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synthon BV
Original Assignee
Synthon BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthon BV filed Critical Synthon BV
Publication of EP3518904A1 publication Critical patent/EP3518904A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents

Definitions

  • Deferasirox is a BCS class II product, demonstrating high permeability and low solubility.
  • the active ingredient is practically insoluble in water and in acid medium, the solubility increasing with pH.
  • Exjade ® is supplied in Europe and US as dispersible tablets for suspension in three different strengths: 125, 250 and 500 mg.
  • the tablet is dispersed in a glass of water or any other suitable drink and the resulting suspension is then administered to the patient.
  • the dispersible tablets have to be taken on an empty stomach at least 30 minutes before a meal.
  • Exjade ® was developed as dispersible tablets with 29.4% drug load. More recently, film-coated oral tablets were developed in the strengths 90, 180 and 360 mg.
  • the film-coated oral tablets contain 55% by weight of deferasirox based on the total weight of the tablet.
  • the tablets do not contain sodium lauryl sulfate as surfactant, but instead poloxamer.
  • the film-coated oral tablets do not contain lactose.
  • WO2004035026 discloses dispersible tablets of deferasirox wherein the active ingredient is present in an amount of from 5 to 40% by weight based on the total weight of the tablet.
  • the application covers the composition of the marketed Exjade ® dispersible tablet for suspension.
  • WO2005097062 discloses dispersible tablets of deferasirox wherein deferasirox is present in an amount of from 42 to 65% by weight based on the total weight of the tablet.
  • WO2007045445 discloses dispersible tablets of deferasirox wherein the active ingredient is present in an amount of from 42 to 65% by weight based on the total weight of the tablet and the tablet further comprises at least one pharmaceutically acceptable excipient suitable for preparing dispersible tablets.
  • WO2009067557 provides a process for preparing formulations of deferasirox with a sufficiently high dissolution rate and good bioavailability, wherein said process comprises co- milling deferasirox in the absence of any solvent with at least two pharmaceutically acceptable excipients.
  • WO2010035282 discloses oral pharmaceutical compositions in the form of dispersible tablets comprising deferasirox wherein the active ingredient has a mean particle size less than about 100 ⁇ and is present in an amount greater than 66% by weight based on the total weight of the tablet.
  • WO2012042224 discloses compositions comprising nanosized deferasirox having improved surface area and solubility.
  • WO2014136079 discloses oral formulations in the form of film-coated oral tablets comprising deferasirox present in an amount of from 45 to 60% by weight based on the total weight of the tablet. This application discloses the composition of the Exjade ® /Jadenu ® film- coated oral tablet.
  • the present invention provides a film-coated swallowable tablet comprising deferasirox in an amount of at least 60% by weight based on the total weight of the tablet and poloxamer, wherein the weight ratio of deferasirox to poloxamer is at least 1:0.002.
  • Said tablet may be used as medicament in the treatment of chronic iron overload.
  • Figure 1 shows the dissolution profiles of the core and coated tablets in accordance with the present invention and the Jadenu ® film-coated oral tablets.
  • the recently developed film-coated oral tablets of Exjade ® /Jadenu ® comprising deferasirox show some significant improvements over the original marketed dispersible tablets for suspension of Exjade ® .
  • a major advantage for patients is that the film-coated oral tablets can be swallowed as such instead of dispersing them first in a suitable drink as the dispersible tablets for suspension require.
  • the film-coated oral tablets do not exhibit the food effect as observed for the dispersible tablets for suspension and the film- coated oral tablets do not give rise to gastrointestinal irritation as observed with the dispersible tablets for suspension.
  • removing lactose from the film- coated oral tablet formulation and replacing the surfactant sodium lauryl sulfate with poloxamer are accountable for the advantages of the film-coated oral tablet over the dispersible tablet for suspension.
  • the film-coated oral Exjade ® /Jadenu ® tablets contain 55% by weight of deferasirox based on the total weight of the tablet. It would be advantageous to increase the drug load of the film-coated oral tablets further resulting in smaller tablets and thereby reducing the pill burden for patients.
  • deferasirox being a low soluble compound with only moderate flowability properties, it is not self-evident to increase the drug load of deferasirox in the film-coated oral tablet even further above 55% by weight based on the total weight of the tablet.
  • a film-coated swallowable tablet comprising deferasirox in an amount of at least 60% by weight based on the total weight of the tablet and poloxamer, wherein the weight ratio of deferasirox to poloxamer is at least 1:0.002 is bioequivalent to the film-coated oral Exjade ® /Jadenu ® tablet, but significantly smaller in size.
  • the tablet is prepared by a robust and cost effective process.
  • the weight ratio of deferasirox to poloxamer in the film-coated swallowable tablet comprising deferasirox in amount of at least 60% by weight based on the total weight of the tablet ranges from 1:002 to 1:008. More preferably, the weight ratio of deferasirox to poloxamer in the tablet ranges from 1:003 to 1:005.
  • deferasirox is present in the film-coated swallowable tablet in an amount of
  • deferasirox is present in an amount of 64 to 67% by weight based on the total weight of the tablet.
  • the poloxamer is present in the film-coated swallowable tablet in an amount of 0.15 to 0.50% by weight based on the total weight of the tablet. More preferably, the poloxamer is present in an amount of 0.20 to 0.35% by weight based on the total weight of the tablet.
  • the wettability of the deferasirox particles is optimal resulting in tablets displaying a dissolution profile that is similar to the profile of the film-coated oral Exjade ® /Jadenu ® tablets.
  • the poloxamer prevents the occurrence of gastrointestinal irritation.
  • Poloxamers are synthetic block copolymers of hydrophilic poly(oxyethylene) and hydrophobic poly(oxypropylene). Properties such as viscosity, HLB and physical state are dependent on the relative chain lengths of the hydrophilic and hydrophobic blocks.
  • Poloxamers are supplied commercially as Pluronic ® , Kolliphor ® , Lutrol ® and Synperonic ® .
  • Poloxamer 188 commercially available as Pluronic ® F-68, Kolliphor ® P 188, Lutrol ® F-68 or Synperonic ® F68, is a particularly preferred non-ionic surfactant to be used in accordance with the present invention.
  • the film-coated swallowable tablet in accordance with the present invention comprising deferasirox and a poloxamer further comprises one or more pharmaceutically acceptable excipients.
  • the excipients to be used in accordance with the present invention are well-known and are those excipients which are conventionally used by the person skilled in the art.
  • the pharmaceutically acceptable excipients are chosen from one or more binders, diluents, disintegrants, glidants or lubricants.
  • the diluent to be used in accordance with the present invention may be any diluent known to a person of ordinary skill in the art.
  • the diluent to be used in accordance with the present invention is an inorganic diluent, polysaccharide, mono- or disaccharide or sugar alcohol.
  • Microcrystalline cellulose is a particularly preferred diluent.
  • the binder to be used in accordance with the present invention may be any binder known to a person of ordinary skill in the art. Suitable binders are selected from the group consisting of celluloses, starch, polyethylene glycol (PEG), sodium carboxymethylcellulose and polyvinyl pyrrolidone (PVP). PVP is a particularly preferred binder.
  • the amount of binder in the film-coated swallowable tablet is between 1.3 and 2.7% by weight based on the total weight of the tablet.
  • the amount of binder in the tablet is between 1.8 and 2.4% by weight based on the total weight of the tablet.
  • the disintegrant to be used in accordance with the present invention may be any disintegrant known to a person of ordinary skill in the art. Suitable disintegrants to be used in accordance with the present invention are selected from the group consisting of
  • PVPP polyvinylpolypyrrolidone
  • the disintegrant is present in an amount of 6.0 to 9.0% by weight based on the total weight of the tablet.
  • the disintegrant is present both intragranularly and extragranularly.
  • the amount of disintegrant present in the intragranular phase is between 5.0 and 6.5% by weight based on the total weight of the tablet.
  • the glidant to be used in accordance with the present invention may be any glidant known to a person of ordinary skill in the art. Colloidal silicon dioxide is a particularly preferred glidant.
  • the amount of glidant in the tablet is between 0.2 and 1% by weight based on the total weight of the tablet. Preferably, the amount is between 0.4 and 0.6% by weight based on the total weight of the tablet.
  • the lubricant to be used in accordance with the present invention may be any lubricant known to a person of ordinary skill in the art.
  • Magnesium stearate is a particularly preferred lubricant. It is present in an amount of 0.5 to 2% by weight based on the total weight of the tablet. Most preferably, the amount of magnesium stearate in the film-coated swallowable tablet is between 1.3 and 1.6% by weight based on the total weight of the tablet.
  • the amount of binder in the swallowable tablet is between 1.3 and 2.7% by weight, the amount of disintegrant is between 6.0 and 9.0% by weight, the amount of glidant is between 0.2 and 1% by weight and the amount of lubricant is between 0.5 and 2% by weight, all based on the total weight of the tablet.
  • the film-coated swallowable tablet comprises between 1.8 and 2.4% by weight of PVP, between 6.0 and 9.0% by weight of PVPP, between 0.4 and 0.6% by weight of colloidal silicon dioxide and between 1.3 and 1.6% by weight of magnesium stearate, all based on the total weight of the tablet.
  • the total amount of intragranular components is preferably between 90 and 95% by weight of the total weight of the tablet.
  • the tablets are further coated by a film-coat.
  • the coating serves generally for cosmetic purposes.
  • the coating material typically has no influence on the release rate, except of an inherent short initial delay in dissolution due to the time necessary to dissolve the coat.
  • the coating may be selected from amongst one or more of those suitable coating materials known in the art. Coating may be performed by applying one or more film forming polymers, with or without other pharmaceutically inert excipients, as a solution/suspension. Coating is done using any conventional coating technique known in the art, such as spray coating in a conventional coating pan or fluidized bed processor, or dip coating.
  • the pharmaceutical composition of the current invention is coated with Opadry ® II, comprising hydroxypropylmethyl cellulose, lactose and triacetin.
  • the particle size of the active pharmaceutical ingredient in the film-coated swallowable tablet of the present invention is not particularly limited. However, it is preferred that the deferasirox in the tablet of the present invention has a D90 particle size equal to or less than 100 ⁇ . More preferably, the D90 particle size of deferasirox is equal to or less than 30 ⁇ . Most preferably, the D90 particle size of deferasirox in the film-coated swallowable tablet is equal to or less than 15 ⁇ . A particularly preferred D90 particle size of deferasirox in the film-coated swallowable tablet in accordance with the present invention is between 4 and 10 ⁇ .
  • the present invention further provides a process to prepare a film-coated swallowable tablet comprising deferasirox in an amount of at least 60% by weight based on the total weight of the tablet and poloxamer, wherein the weight ratio of deferasirox to poloxamer is at least 1:0.002 comprising granulation.
  • the granulation process applied is a standard wet granulation technique, using equipment and methods well-known in the art.
  • the granulation process to prepare the film-coated swallowable tablet consists of two steps.
  • the aim of the first step is not to obtain granules, but to distribute the surfactant homogeneously over the active pharmaceutical ingredient (API) thereby lowering the interfacial tension between the hydrophobic and poorly soluble API particles.
  • the disintegrant and part of the binder are included in this step as well.
  • the aim of the second step is to obtain the final granules by adding the remaining intragranular excipients, viz. diluent and the second part of the binder.
  • the amount of granulation liquid used is between 30 and 45% based on the total intragranular weight.
  • the appearance, disintegration time and dissolution of the granules are optimal, resulting in tablets displaying a dissolution profile that is similar to the profile of the film-coated oral Exjade ® /Jadenu ® tablets.
  • the amount of granulation liquid applied is below 30%, a relatively high amount of fines is obtained affecting the physical properties of the granules.
  • the amount of granulation liquid is between 33 and 42% based on the total intragranular weight. More preferably, the amount of granulation liquid is between 35 and 40% based on the total intragranular weight.
  • the granulation liquid to be used in accordance with the present invention may be any granulation liquid known to a person of ordinary skill in the art.
  • a particularly preferred granulation liquid is water.
  • the tablet composition of the present invention displays dissolution behavior typical for immediate-release formulations.
  • the film-coated swallowable tablet in accordance with the present invention exhibits a dissolution rate of at least 80% in 20 minutes and at least 90% in 30 minutes when tested in 900 ml phosphate buffer pH 6.8 (+ 0.5% Tween ® 20) in a USP apparatus II with vessels at 75 rpm (FDA dissolution method) or peak vessels at 50 rpm.
  • the film-coated swallowable tablets of the present invention are preferably packed in blister pack material.
  • the blister pack material to be used in accordance with the present invention may be any blister pack material known to a person of ordinary skill in the art. Suitable blister pack materials to be used in accordance with the present invention are selected from the group of PVC/Alu, PVDC/PVC/Alu and Alu/Alu. A particularly preferred blister pack material to be used in accordance with the present invention is PVDC/PVC/Alu.
  • the film-coated swallowable tablet of the present invention exhibits excellent long term stability. Moreover, the pharmaceutical composition of the present invention is very suitable for production on commercial scale making use of equipment and techniques commonly used in industry.
  • the film-coated swallowable tablet in accordance with the present invention may be used as a medicament.
  • the tablet typically may be used in the treatment of chronic iron overload.
  • the following examples are intended to illustrate the scope of the present invention but not to limit it thereto.
  • Example 1 Pharmaceutical composition comprising 65 wt% deferasirox and 0.25 wt% poloxamer 188
  • the tablets comprising 65 wt deferasirox and 0.25 wt poloxamer 188 have the composition as given in table 1.
  • Poloxamer 188 and half of the total amount of povidone K30 were dissolved in water. Deferasirox and crospovidone were mixed in a high shear mixer. The solution containing the poloxamer and povidone K30 was added. A granulation (first step) was carried out.
  • Microcrystalline cellulose was added and the mixture was mixed in the high shear mixer.
  • the other half of the total amount of povidone K30 was dissolved in water and the resulting aqueous solution was added to the high shear mixer and a granulation (second step) was carried out.
  • the wet granules were sieved and dried in a fluid bed at 60-80°C.
  • the granules were sieved and transferred into an appropriate bin blender.
  • Microcrystalline cellulose, crospovidone and colloidal silicon dioxide were sieved, added to the blender and the mixture was mixed. Magnesium stearate was sieved and mixed with the blend in the bin blender.
  • the homogeneous blend was compressed under controlled humidity on a tablet press.
  • the tablets were coated with Opadry ® II.
  • the tablets were packed in blisters.
  • the tablets obtained exhibit a dissolution rate of at least 80% in 20 minutes and at least 90% in 30 minutes when tested in 900 ml phosphate buffer pH 6.8 (+ 0.5% Tween ® 20) in a USP apparatus II with vessels at 75 rpm or peak vessels at 50 rpm.
  • the dissolution profiles of the tablets are similar to the profiles of the film-coated oral Exjade ® /Jadenu ® tablets.
  • Figure 1 shows the dissolution profiles of the core and coated tablets prepared following the process as described in this example and the Jadenu ® film-coated oral tablets.
  • the tablets obtained are bioequivalent to the film-coated oral Exjade ® /Jadenu ® tablets.

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un comprimé avalable pelliculé comprenant du déférasirox dans une quantité d'au moins 60 % en poids sur la base du poids total du comprimé et du poloxamère, le rapport en poids du déférasirox au poloxamère étant d'au moins 1:0,002. L'invention concerne en outre l'utilisation dudit comprimé comme médicament dans le traitement de la surcharge en fer chronique.
EP17769011.2A 2016-09-30 2017-09-11 Composition pharmaceutique comprenant du deferasirox Pending EP3518904A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16191967 2016-09-30
PCT/EP2017/072747 WO2018059922A1 (fr) 2016-09-30 2017-09-11 Composition pharmaceutique comprenant du deferasirox

Publications (1)

Publication Number Publication Date
EP3518904A1 true EP3518904A1 (fr) 2019-08-07

Family

ID=57103853

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17769011.2A Pending EP3518904A1 (fr) 2016-09-30 2017-09-11 Composition pharmaceutique comprenant du deferasirox

Country Status (2)

Country Link
EP (1) EP3518904A1 (fr)
WO (1) WO2018059922A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR1009592B (el) * 2018-07-03 2019-09-11 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει εναν χηλικο παραγοντα συμπλεκτικο του σιδηρου και μεθοδος για την παρασκευη αυτου
WO2022186809A1 (fr) * 2021-03-05 2022-09-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Comprimé pelliculé comprenant du déférasirox

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW533205B (en) 1996-06-25 2003-05-21 Novartis Ag Substituted 3,5-diphenyl-l,2,4-triazoles and their pharmaceutical composition
GB0223978D0 (en) 2002-10-15 2002-11-20 Novartis Ag Organic compound
GB0408078D0 (en) 2004-04-08 2004-05-12 Novartis Ag Organic compounds
CN101291655A (zh) 2005-10-19 2008-10-22 诺瓦提斯公司 包含地拉罗司(deferasirox)的分散片
US20090142395A1 (en) 2007-11-19 2009-06-04 Uri Zadok Deferasirox pharmaceutical compositions
WO2010035282A1 (fr) 2008-09-24 2010-04-01 Matrix Laboratories Limited Compositions pharmaceutiques comprenant du deferasirox
KR20140011300A (ko) 2010-10-01 2014-01-28 시플라 리미티드 데페라시록스를 포함하는 약학 조성물
SG10201807204YA (en) 2013-03-08 2018-09-27 Novartis Ag Oral formulations of deferasirox

Also Published As

Publication number Publication date
WO2018059922A1 (fr) 2018-04-05

Similar Documents

Publication Publication Date Title
NZ560829A (en) A solid pharmaceutical dosage formulation
AU2014345629B2 (en) Mesoporous dosage forms for poorly soluble drugs
WO2017032908A1 (fr) Composition pharmaceutique comprenant du posaconazole amorphe
EP2902016A1 (fr) Comprimé Febuxostat
EP3793530A1 (fr) Dispersion solide contenant du ritonavir
JP2017523149A (ja) エドキサバンの医薬組成物
US20220347102A1 (en) Pharmaceutical composition comprising enzalutamide
EP2804588B1 (fr) Procédé de préparation de compositions de cinacalcet destinées à la fabrication directe de comprimés
EP3518904A1 (fr) Composition pharmaceutique comprenant du deferasirox
EP3817728B1 (fr) Composition pharmaceutique comprenant un agent chélateur de fer et son procédé de préparation
EP3694492A1 (fr) Composition de comprimé à libération modifiée comprenant du mirabegron
AU2020397233A1 (en) Pharmaceutical composition comprising eltrombopag bis(monoethanolamine)
US11260055B2 (en) Oral pharmaceutical composition of lurasidone and preparation thereof
EP2471520A1 (fr) Compositions pharmaceutiques de lévétiracetam
EP3618814A1 (fr) Comprimés pelliculés de déférasirox
KR20100045439A (ko) 수용성 빈노렐빈 염의 안정적인 약학적 조성물
EP4444276A1 (fr) Composition pharmaceutique comprenant de l'ibrutinib
WO2023084545A1 (fr) Composition pharmaceutique stable d'antiandrogènes non stéroïdiens
WO2016042568A1 (fr) Formulation à libération prolongée de gliclazide
JP2024532885A (ja) 医薬組成物及びその調製方法
EP3928771A1 (fr) Compositions pharmaceutiques de 1,2-benzisoxazole-3-methanesulfonamide
WO2024121413A1 (fr) Formulation contenant de l'édoxaban et sa préparation
WO2016042566A1 (fr) Formulation de trimétazidine à libération prolongée
WO2016042567A1 (fr) Formulation de metformine à libération prolongée
WO2016042565A1 (fr) Formulation à libération prolongée de métoprolol

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190430

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20220523

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230615